International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis

Terminated

• Conditions: Allergic Rhinitis Due to Grass Pollens

• Registration Number: NCT02041624
• Lead Sponsor: Stallergenes Greer

Brief Summary

The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.

Detailed Description

Primary objective:

To describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass pollen season in real-life settings.

Secondary objectives:

- To describe the patient's perceived effectiveness of ORALAIR® in allergic rhinoconjunctivitis management in terms of disease intensity, satisfaction and rescue medication

Study Timeline

• Study First Submitted: 2014-01-14
• Study First Submitted QC: 2014-01-17
• Study First Posted: 2014-01-22
• Study Start: 2014-05
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2016-04
• Last Update Submitted: 2016-04-15
• Last Update Posted: 2016-04-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 740

Inclusion Criteria

• Patient of 5 years of age and older at the date of the screening visit
• Patient with proven allergic rhino-conjunctivitis due to grass pollen
• Patient eligible for a grass-pollen Allergen ImmunoTherapy (AIT)
• Patient whose physician prescribed ORALAIR® independently of the study, before the beginning of the grass-pollen season

Exclusion Criteria

• Patient participating in a clinical trial or in an epidemiological study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Health related quality of life	patients will be followed for the duration of the treatment, an expected average of 6 months/year	The primary objective is to describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass-pollen season in real-life settings.

Secondary Outcome Measures

Name	Time	Method
Treatment Effectiveness	patients will be followed for the duration of the treatment, an expected average of 6 months/year	To describe the patient's perceived effectiveness of ORALAIR® in allergic rhino-conjunctivitis management in terms of disease intensity, satisfaction and rescue medication

Trial Locations

Locations (1)

Laboratoire Stallergenes; 🇫🇷 Antony, France